Detalhe da pesquisa
1.
Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres.
Mult Scler
; 28(2): 257-268, 2022 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-33975489
2.
Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM.
BMC Neurol
; 16: 48, 2016 Apr 16.
Artigo
Inglês
| MEDLINE | ID: mdl-27083892
3.
Cell stress molecules in the skeletal muscle of GNE myopathy.
BMC Neurol
; 13: 24, 2013 Mar 12.
Artigo
Inglês
| MEDLINE | ID: mdl-23496965
4.
Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine.
Cells
; 12(9)2023 04 25.
Artigo
Inglês
| MEDLINE | ID: mdl-37174643
5.
Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab.
Neurol Neuroimmunol Neuroinflamm
; 10(3)2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-37041077
6.
Immunological consequences of cladribine treatment in multiple sclerosis: A real-world study.
Mult Scler Relat Disord
; 64: 103931, 2022 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-35690010
7.
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.
Neurol Neuroimmunol Neuroinflamm
; 8(5)2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34261812
8.
HMGB1 and RAGE in skeletal muscle inflammation: Implications for protein accumulation in inclusion body myositis.
Exp Neurol
; 271: 189-97, 2015 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-26048613